Novartis Pharmaceuticals Corporation recalls Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2 mL each via
Recalled June 15, 2022 · FDA recall D-0984-2022 · Novartis Pharmaceuticals
Hazard
Failed Impurities/Degradation Specifications. · FDA Class III
Units
279,179 vials
Sold at
Nationwide within the United States
Description
Failed Impurities/Degradation Specifications.
Product
Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2 mL each vial) (NDC 0078-0911-95) and b) 4 pouches x 5 single-use containers (NDC 0078-0911-94), Rx Only, Manufactured by: The Ritedose Corporation Columbia, SC 29203; Distributed by: Novartis Pharmaceuticals Corporation East Hanover, NJ 07936.
Manufacturer(s)
Novartis Pharmaceuticals Corporation
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →